NeuroVive Entering Chinese Market with Sihuan Alliance
By Nuala Moran
Wednesday, November 28, 2012
LONDON NeuroVive Pharmaceutical AB signed a deal for the development of its two lead mitochondria-sparing programs in China to add to a similar agreement in Europe that should see the two drugs through to commercialization in both markets.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.